viewLancor Scientific

Lancor Scientific to have its screening device approved for six cancers by March

Lancor Scientific's Roland Schlesinger updates Proactive London's Andrew Scott on latest developments with their cancer screening device.

He says they've already got one cancer device approved with five more soon to follow.

''We're in the process of moving towards mass production capabilities which should be complete by the end of January ... and then we'll be ready for sales''.

''The pre-sales of everything based on our current regulatory status can start around the end of October or November''.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lancor Scientific named herein, including the promotion by the Company of Lancor Scientific in any Content on the Site, the Company receives...



Medtech disruptor Lancor Scientific strengthens its marketing team

Lancor Scientific's CEO Aamir Butt and Head of Marketing & Global Access Dr. Donald De Korte tell Proactive London how the company is now poised, after 10 years of R&D, to deliver low cost cancer screening to millions. Lancor recently gained permission to work in a cancer research...

on 23/4/19

2 min read